Spectrum Pharmaceuticals, Inc. (nasdaqgm:SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced that Rajesh C. Shrotriya, MD, Chairman of the Board, Chief Executive Officer, and President, will ring the Nasdaq Stock Market opening bell on Tuesday, September 28, 2010.
"We are excited to ring the Nasdaq opening bell on Tuesday, September 28, 2010," said Dr. Shrotriya. "We have made great strides over the past 8 years since I was appointed CEO and we started Spectrum Pharmaceuticals with a focus in oncology. Today, we are proud that our two FDA approved drugs, ZEVALIN(R) and FUSILEV(R), are on the market helping cancer patients. This year we expect to generate more than $30 million in product revenue. In addition, we expect two potential NDA filings with the FDA, belinostat in 2011 and apaziquone in 2012. We also have a broad and deep pipeline of promising drug candidates. With more than $90 million in cash and equivalents as of June 30, 2010, and approximately 150 employees engaged in developing and bringing novel cancer treatments to market, we look forward to helping more cancer patients in the years to come."
No comments:
Post a Comment